Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 12 recruiting now full pipeline

Sarcoidosis: full-pipeline trial registry

12 of 22 indexed Sarcoidosis trials are currently recruiting.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 12 currently recruiting · #756 of 28,707 conditions by registered trial count

Sarcoidosis: 22 US clinical trials tracked, 12 recruiting.

Sarcoidosis is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Kansas Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition sarcoidosis

OPEN 12 | RECR 55% | LATE 4 | EARLY 3 | RANK #756 | SPON 2

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Advanced Melanoma63.6%Sarcoidosis (this)55%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Sarcoidosis

Sarcoidosis lists 12 open slots (55% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sarcoidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sarcoidosis is recruiting above its size-band peers.

    12 of 22 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Sarcoidosis trials is spread across many organizations.

    University of Kansas Medical Center accounts for 2 of 22 trials (9.1%). 19 distinct sponsors appear on at least one study for this condition label.

  3. Typical Sarcoidosis enrolment sits around 125 participants.

    Median target enrolment is 125 among the 22 trials that report a genuine target (sentinel values excluded). 9 of those (40.9%) plan for fewer than 100 participants.

  4. Sarcoidosis splits between interventional and observational designs.

    10 interventional and 12 observational studies make up this index (45.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 31Phase 43

Open and recent trials

22 total, page 1 of 1

RECRUITING 27,000 participants

Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

Duke University

NCT01745237

RECRUITING 6,833 participants

Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)

Foundation for Sarcoidosis Research

NCT06234384

RECRUITING 5,000 participants

Cardiovascular Multimodality Imaging Study

Montefiore Medical Center

NCT06610019

RECRUITING 4,000 participants

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

University of Chicago

NCT00470327

RECRUITING 1,000 participants

Interstitial Lung Disease Research Unit Biobank

University of Kansas Medical Center

NCT05392881

RECRUITING Phase 3 194 participants

Cardiac Sarcoidosis Randomized Trial

Ottawa Heart Institute Research Corporation

NCT03593759

RECRUITING 125 participants

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

Oregon Health and Science University

NCT07065747

RECRUITING NA 120 participants

Cell Free DNA in Cardiac Sarcoidosis

Nabeel Hamzeh

NCT03858777

RECRUITING NA 100 participants

Virtual Patient Groups for Sarcoidosis Associated Fatigue

The Cleveland Clinic

NCT07073963

RECRUITING Phase 4 90 participants

Vitamin D Homeostasis in Sarcoidosis

University of Texas Southwestern Medical Center

NCT03621553

RECRUITING 20 participants

Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens

Johns Hopkins University

NCT05171478

RECRUITING Phase 4 14 participants

Use of CXCL9 as a Biomarker of Acthar Efficacy

University of California, San Francisco

NCT02523092

ACTIVE NOT RECRUITING 150 participants

Medication Adherence in Patients With Sarcoidosis

Johns Hopkins University

NCT05438095

COMPLETED 400 participants

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

National Jewish Health

NCT00560989

COMPLETED 239 participants

CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases

4YouandMe

NCT06907953

COMPLETED 171 participants

Association Between Cancer and Sarcoidosis

University of Miami

NCT03844698

COMPLETED NA 24 participants

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

University of North Carolina, Chapel Hill

NCT01615484

COMPLETED Phase 4 20 participants

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

University of Cincinnati

NCT00403650

COMPLETED 19 participants

Evaluation of MyoStrain™ in Clinical Practice

University of Kansas Medical Center

NCT03825224

COMPLETED Phase 2 16 participants

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Medical University of South Carolina

NCT00851929

COMPLETED Early Phase 1 15 participants

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

Yale University

NCT03048097

COMPLETED Phase 2 10 participants

Janus Kinase Inhibition in Sarcoidosis

Yale University

NCT05696795

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1
Phase 4 3

Named interventions

Most-linked intervention names on Sarcoidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Observational - no intervention Other
1 trials
Diagnostic Test: Myostrain Procedure
1 trials
FDG-PET/CT with Rb82 Myocardial Perfusion Imaging Diagnostic test
1 trials
Rubidium Drug
1 trials
Iloprost Drug
1 trials
Ambrisentan Drug
1 trials
STEEN Solution™ Device
1 trials
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™ Procedure
1 trials

US sites by state

Facility locations filed on Sarcoidosis trials. A trial with sites in several states counts in each.

Ohio 3 trials
New York 3 trials
North Carolina 3 trials
Connecticut 3 trials
Maryland 2 trials
Kansas 2 trials
Illinois 2 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sarcoidosis page

22 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoidosis condition card totals 22 registered trials; most-linked intervention Observational - no intervention; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.